ALLO Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of 10.59%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 364.36%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 34.6%. Given that Allogene Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..

Allogene Therapeutics, Inc. has a beta of 0.512, which suggesting that the stock is 48.816% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.

Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 2.01x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of -2301.55%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 364.36%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 80.72%. Given that Allogene Therapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Allogene Therapeutics, Inc. has a beta of 0.512, which suggesting that the stock is 48.816% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 55.08x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of -12425.36%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 364.36%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 188.91%. Given that Allogene Therapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..

Allogene Therapeutics, Inc. has a beta of 0.512, which suggesting that the stock is 48.816% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 288.85x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of 13.19%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 364.36%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 431.4%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Allogene Therapeutics, Inc..

Allogene Therapeutics, Inc. has a beta of 0.512, which suggesting that the stock is 48.816% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 29.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 2.63x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.